SOX2 and gastric cancer: Studies have strongly associated SOX2 to these respective cancer hallmarks and thus far SOX2 has been shown to promote cellular proliferation (breast, prostate, pancreatic and cervical cancers) [21,28,57,58], evade apoptotic signals (prostate, gastric cancer and NSCLC) [37,58,63] and promote invasion, migration and metastasis (melanoma, colorectal, glioma, gastric, ovarian cancer and hepatocellular carcinoma) [15,29,47,49,55].